Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Blood-brain-barrier dynamics in healthy aging and Alzheimer's disease

FY 2020-21

Summary
During the normal aging process, about 40% of people >65 years old experience memory loss unattributable to disease, classified as aging-related memory-loss. However, Alzheimer's disease (AD) and other dementias pathologically affect our brains. Over 500K Canadians are currently living with AD or other dementias, and this number is projected to double to 1M in 2031. In 2019, the Canadian government released the country's first dementia strategy with 3 objectives: (1) prevent dementia, (2) advance therapies and find a cure, and (3) improve the quality of life of people living with dementia and their caregivers. In order to follow through on these objectives, more research needs to be done in order to understand the underlying cause of AD in the aging population. We hypothesize that the breakdown of the blood-brain-barrier (BBB) plays a key role in the progression of AD. This proposal, through the use of high-dimensional neuroimaging, aims to find key differences between aging-AD-BBB dynamics. Neuroimaging is critical to understand the cellular and structural landscape of the brain. We aim to understand the spatial landscape of the BBB to understand the interplay between physiology, metabolism, pathology, and immunology in aging and AD, which can: (1) identify risk factors for AD, (2) uncover therapeutic targets to manage the disease, and (3) aid in understanding of the disease progression mechanisms - concordant with Canada's dementia strategy. We will use multiplexed ion beam imaging (MIBIscope) to characterize and spatially localize BBB features contributing to disease in donor brains. Unlike current technologies, MIBIscope will allow us to look at >40 proteins simultaneously, which have a role in AD, and examine how they interact with one another. This approach will allow us to understand the role the BBB dynamics play in healthy aging and AD pathology, and potentially identify therapeutic targets for the development of novel drugs to manage AD.
Program
Banting Postdoctoral Fellowship Program
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
436088
Name
Oliveria John Paul T
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Blood-brain-barrier dynamics in healthy aging and Alzheimer's disease
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Alzheimer'S Disease; Astrocytes; Blood Brain Barrier; Brain Aging; Cognition; Dementia; Neuroimaging; Neuroimmunology; Neuropathology; Neurovasculature
Abstract
During the normal aging process, about 40% of people >65 years old experience memory loss unattributable to disease, classified as aging-related memory-loss. However, Alzheimer's disease (AD) and other dementias pathologically affect our brains. Over 500K Canadians are currently living with AD or other dementias, and this number is projected to double to 1M in 2031. In 2019, the Canadian government released the country's first dementia strategy with 3 objectives: (1) prevent dementia, (2) advance therapies and find a cure, and (3) improve the quality of life of people living with dementia and their caregivers. In order to follow through on these objectives, more research needs to be done in order to understand the underlying cause of AD in the aging population. We hypothesize that the breakdown of the blood-brain-barrier (BBB) plays a key role in the progression of AD. This proposal, through the use of high-dimensional neuroimaging, aims to find key differences between aging-AD-BBB dynamics. Neuroimaging is critical to understand the cellular and structural landscape of the brain. We aim to understand the spatial landscape of the BBB to understand the interplay between physiology, metabolism, pathology, and immunology in aging and AD, which can: (1) identify risk factors for AD, (2) uncover therapeutic targets to manage the disease, and (3) aid in understanding of the disease progression mechanisms - concordant with Canada's dementia strategy. We will use multiplexed ion beam imaging (MIBIscope) to characterize and spatially localize BBB features contributing to disease in donor brains. Unlike current technologies, MIBIscope will allow us to look at >40 proteins simultaneously, which have a role in AD, and examine how they interact with one another. This approach will allow us to understand the role the BBB dynamics play in healthy aging and AD pathology, and potentially identify therapeutic targets for the development of novel drugs to manage AD.
Competitiondate
202010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Oliveria, John Paul T
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~